1	User involvement in the design and development of medical				
2	devices in Epilepsy: a systematic review				
3	João Ferreira <sup>1,2</sup> *, Ricardo Peixoto <sup>1,2</sup> , Lígia Lopes <sup>1,3</sup> , Sándor Beniczky <sup>4,5,6</sup> , Philippe Ryvlin <sup>7</sup> ,				
4	Carlos Conde <sup>8,9,10</sup> * and João Claro <sup>1,11*</sup>				
5					
6	<sup>1</sup> Faculty of Engineering, University of Porto, Portugal.				
7	<sup>2</sup> Biostrike Unipessoal Lda, Porto, Portugal				
8	<sup>3</sup> FBAUP – Faculty of Fine Arts, University of Porto, Portugal.				
9	<sup>4</sup> Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark				
10	<sup>5</sup> Department of Clinical Medicine, Aarhus University, Aarhus, Denmark				
11	<sup>6</sup> Department of Clinical Neurophysiology, Danish Epilepsy Center, Dianalund, Denmark				
12	<sup>7</sup> Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne,				
13	Switzerland				
14	<sup>8</sup> i3S, Instituto de Investigação e Inovação em Saúde, University of Porto, Portugal.				
15	<sup>9</sup> School of Medicine and Biomedical Sciences, University of Porto, Portugal.				
16	<sup>10</sup> Institute for molecular and cell biology, University of Porto, Portugal				
17	<sup>11</sup> INESC TEC, Porto, Portugal				
18					
19					
20	* Authors for correspondence:				
21	João Ferreira (joao.ferreira@biostrike.pt) ORCID: 0000-0002-5827-0623.				
22	Rua Sousa Aroso 31 Ed.2 1°B				
23	4450-289 Matosinhos, Portugal				
24	+351 916520265 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.				

2	-
/	<b>ר</b>
~	-

- 26 Carlos Conde (<u>cconde@ibmc.up.pt</u>) ORCID: 0000-0002-4177-8519.
- 27 Rua Alfredo Allen 208,
- 28 4200-135, Porto, Portugal
- 29 +351 22 607 4900
- 30
- 31 João Claro (jclaro@fe.up.pt) ORCID: 0000-0001-5936-1036
- 32 INESC TEC and Faculdade de Engenharia, Universidade do Porto, Campus da FEUP, Rua
- 33 Dr. Roberto Frias, 4200-465 Porto, Portugal
- 34 +351 22 508 1400
- 35
- 36 Key Words for use by abstracting services: epilepsy, medical devices, user involvement,
- 37 medical device design

- 39 Number of text pages: 43
- 40 Number of words: 4507
- 41 Number of references: 90
- 42 Number of figures: 6
- 43 Number of tables: 3
- 44
- 45
- 46
- 47
- 48
- 49

# 50 ABSTRACT

Objective This systematic review aims to describe the involvement of persons with epilepsy
(PWE), healthcare professionals (HP) and caregivers (CG) in the design and development of
medical devices is epilepsy.

Methods: A systematic review was conducted, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligibility criteria included peer-reviewed research focusing on medical devices for epilepsy management, involving users (PWE, CG, and HP) during the MDD process. Searches were performed on PubMed, Web of Science, and Scopus, and a total of 55 relevant articles were identified and reviewed.

**Results:** From 1999 to 2023, there was a gradual increase in the number of publications 59 60 related to user involvement in epilepsy medical device development (MDD), highlighting the 61 growing interest in this field. The medical devices involved in these studies encompassed a range of seizure detection tools, healthcare information systems, vagus nerve stimulation 62 63 (VNS) and electroencephalogram (EEG) technologies reflecting the emphasis on seizure detection, prediction, and prevention. PWE and CG were the primary users involved, 64 underscoring the importance of their perspectives. Surveys, usability testing, interviews, and 65 focus groups were the methods employed for capturing user perspectives. User involvement 66 occurs in four out of the five stages of MDD, with production being the exception. 67 **Significance** User involvement in the MDD process for epilepsy management is an emerging 68 area of interest holding a significant promise for improving device quality and patient 69 outcomes. This review highlights the need for broader and more effective user involvement, 70 as it currently lags in the development of commercially available medical devices for 71 epilepsy management. Future research should explore the benefits and barriers of user 72 involvement to enhance medical device technologies for epilepsy. 73

#### 75 Plain Language Summary

This review covers studies that have involved users in the development process of medical 76 devices for epilepsy. The studies reported here have focused on getting input from people 77 with epilepsy, their caregivers, and healthcare providers. These devices include tools for 78 79 detecting seizures, stimulating nerves, and tracking brain activity. Most user feedback was gathered through surveys, usability tests, interviews, and focus groups. Users were involved 80 81 in nearly every stage of device development except production. The review highlights that involving users can improve device quality and patient outcomes, but more effective 82 83 involvement is needed in commercial device development. Future research should focus on the benefits and challenges of user involvement. 84

85

86 Keywords: epilepsy, medical devices, user involvement, medical device design

87 Key Point Box

- PWE are the users more involved in the MDD process;

- Surveys and usability testing are the methods more frequently used for user
  involvement in the MDD process in epilepsy;
- Literature only discloses the involvement of users in the MDD process of 13
   commercially available medical devices for epilepsy management.
- 93 **1. INTRODUCTION**

Epilepsy impacts approximately 70 million individuals and 30 % of them do not respond to current treatments to control their seizures <sup>1</sup>. Accurately anticipating the onset of seizures and managing them can assist PWE in avoiding self-injury and potentially enhance their overall well-being. Seizure detection and, more recently, seizure forecasting are critical areas of clinical advancement in epilepsy. The progress in these areas has been driven by 99 developments in medical devices, which have the potential to optimize seizure control and
 100 prevent seizure-related morbidity and mortality in individuals with epilepsy <sup>2</sup>.

101 Medical devices used in epilepsy range from implantable devices such as vagus nerve 102 stimulators, responsive neurostimulation and deep brain stimulation to non-implantable 103 devices such as electroencephalography (EEG) based systems and non-EEG based seizure 104 detection wearable devices <sup>1</sup>. Regardless of the type of medical device, the ultimate goal is to 105 develop devices that meet the needs of end-users (PWE, CGs and HP), improve disease 106 outcomes, and enhance the overall quality of life of individuals with epilepsy.

Medical device manufacturers create life-changing innovations through the collaborative 107 expertise of various disciplines, including engineering, manufacturing, clinical, regulatory, 108 109 marketing, sales, and business specialists. While cutting-edge technology advancement in 110 medical device design is absolutely vital, it is the overall experience (cognitive and emotional) that impacts the daily life of the patient and CG<sup>3</sup>. In recent years, there has been a 111 growing recognition of the importance of user involvement in MDD in general <sup>4</sup>, and 112 specifically for epilepsy <sup>5</sup>. In epilepsy, user involvement refers to the active participation of 113 PWE, CGs, HP and other stakeholders in the design and development of medical devices. 114 Understanding and incorporating users' needs, preferences, and feedback into the MDD 115 process can help to ensure that the device is effective, safe, and well-received by the intended 116 117 users. User involvement can take various forms, including needs assessment, usability testing, co-creation and co-design <sup>6</sup>. User-centred design is a critical factor in the design and 118 development of medical devices. Specifically, considering user needs during the early stages 119 120 of device conceptualization and throughout the subsequent development process can yield substantial benefits. This approach can improve patient safety, increase compliance with 121 treatment regimens, and enhance health outcomes <sup>7</sup>. Additionally, user-centred design 122 promotes higher levels of user satisfaction, and it can lead to a reduction in device 123

development time by identifying and addressing usability issues prior to launch. This, in turn, can help to avoid costly design changes and product recalls, which can have significant financial and reputational implications for device manufacturers <sup>8</sup>. Therefore, successful medical device innovation requires investigation of end-user and broader stakeholder contexts and incorporation of those context-specific needs into design processes <sup>9</sup>.

129 Despite the initial promise that user involvement in medical device design and development for epilepsy holds, there is widespread scepticism regarding its effectiveness within the 130 scientific, medical, and general communities, leaving important choices and questions open 131 for debate, namely: (i) who should be involved, (ii) at which stages should they be involved, 132 (iii) which participatory methods are most suitable and (iv) what topics are to be discussed 133 with end users during development. Therefore, we conducted a systematic review to explore 134 the practice of user involvement in the design and development of medical devices for 135 epilepsy, aiming to provide valuable insights into the role of user involvement in this context 136 and inform future research and practice in this area. Descriptive statistics and qualitative 137 thematic analysis were used for analysing the data, which were divided into different themes, 138 i.e., types of medical devices developed and assessed; types of medical device users involved; 139 140 extent of user involvement by different stages of the MDD cycle; and methods used for capturing users' perspectives. 141

# 142 **2. METHODS**

143 The present systematic literature review was performed to identify and extract all currently 144 available literature related to user involvement in medical devices or technology utilized in 145 the monitoring, treatment and/or management of epilepsy.

## 146 **2.1 Protocol and registration**

147 This systematic review was reported according to the Preferred Reporting Items for 148 Systematic Reviews and Meta-Analyses (PRISMA) guidelines <sup>10</sup>, and was prospectively 149 registered on the International Prospective Register of Systematic Reviews (PROSPERO) 150 (CRD42023490599).

## 151 **2.2 Eligibility Criteria**

Publications inclusion and eligibility for short-listing criteria encompassed (a) peer-reviewed original research, (b) targeted only at medical devices according to WHO's definition <sup>11</sup> with application for epilepsy management and (c) indicating user (PWE, CG and HP) involvement during these products' development lifecycle.

Original publications were excluded if presenting any of the following characteristics: the wrong population (i.e., non-human population); the wrong intervention (i.e., medical devices used for other purposes rather than epilepsy management); the wrong outcome (i.e., there were no epilepsy or seizure diagnosis, management, or treatment outcomes); publication not available in the English language; publications not in full publication. All studies published up to 30 November 2023 were included with no other time limitations.

## 162 **2.3 Search strategy**

Search strings related to medical devices, users' (PWE, CG and HP) involvement and epilepsy were developed. Thus, the search term ("epilepsy") was searched in combination with the following search strings: ("device users" OR "end-users" OR "medical devices" OR "medical device users" OR "needs assessment" OR "new medical technology" OR "user centered product" OR "user criteria" OR "user input" OR "user interests" OR "user involvement" OR "user needs" OR "user needs assessment" OR "user needs research" OR "user participation" OR "user perceptions" OR "user perspective" OR "user requirements"

OR "user requirements elicitation" OR "user studies" or "user survey" OR "user-based" OR
"wearable device" OR "device" and "acceptability" OR ("device" AND "usability") OR
("device" AND "satisfaction") OR ("device" AND "patient views")). The Boolean operator
AND was used to link the search term with the respective search strings on all databases.

Three databases were used from database inception on 30 November 2023: PubMed, Web of 174 175 Science and Scopus. All searches were performed based on the title, abstract and keyword in all databases. Articles were first screened through their titles and abstracts before proceeding 176 with the full-text screening of relevant articles. The search criteria and keywords were arrived 177 at through consensus with all researchers. Hand searching, personal collections (unpublished 178 studies, conference abstracts, grey literature, or other resources that researchers have 179 accumulated through personal networks or professional contacts) and exploding references 180 (reviewing the reference lists of relevant articles to identify additional studies that may not 181 have been captured through our primary search strategy) were also used to augment the 182 183 results.

#### 184 2.4 Selection Process

Database search results were imported into EndNote (EndNote x9; Clarivate, Philadelphia, PA, USA), and duplicates were removed. Results were then exported to an Excel spreadsheet for title, abstract, and full-text screening. Study selection, data extraction and assessment of study quality followed the Standards for Reporting Qualitative Research<sup>13</sup>. No assumptions were made during the selection to reduce the risk of bias. Each paper was screened and discussed by two independent reviewers (JF, RP). Disagreements were resolved by a third independent researcher (CC).

# 192 **2.5 Data collection and analysis**

Data was extracted using a data-extraction form (Appendix 1.) developed for the review  $^{14}$ . 193 Data extracted included: (1) author details, (2) year of publication, (3) country of study, (4) 194 type of medical device, (5) method/tool/approach, (6) users and (7) product development 195 stages. Since there is no standard framework to describe the MDD stages <sup>15</sup>, for data 196 extraction purposes, the medical device lifecycle was divided into five stages: 1- Concept; 2-197 Design; 3-Testing and Trials; 4- Production; 5-Deployment. The classification of medical 198 device lifecycle stages was carried out based on the product lifecycle reported in the literature 199 (Table 1 adapted from Shah, Robinson <sup>16</sup>). 200

201

# 202 **3. RESULTS**

The study workflow and paper selection process is illustrated in Figure 1. Following the 203 inclusion criteria review, 55 publications (<sup>17 18 19 20 21 22 23 24 25</sup>; <sup>26</sup>; <sup>27</sup>; <sup>28</sup>; <sup>29</sup>; <sup>30</sup>; <sup>31</sup>; <sup>32</sup>; <sup>33</sup>; <sup>34</sup>; <sup>35</sup>; 204 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 205 <sup>67</sup>; <sup>68</sup>; <sup>69</sup>; <sup>70</sup>; <sup>71</sup>) were included, and 109 were excluded (see Figure 1 for PRISMA flow chart). 206 Seventeen of the 55 included publications were from the United States, 7 from the United 207 Kingdom, 6 from Canada, 5 from Denmark, 4 from The Netherlands, 3 from Germany and 3 208 from South Korea and 1 from Sweden, 1 from Mexico, 1 from France, 1 from Italy and 1 209 210 from Belgium. Five studies were of multiple origin (Table S1).

Across the years, we find that user involvement in MDD is becoming more frequent. Figure 2 shows the number of papers published per year and the total accumulated number of publications over time since the inaugural paper by Hufford, R.L., P.M.<sup>72</sup>.

#### **3.1** Types of medical devices assessed by user involvement.

In our comprehensive review, we have identified a broad spectrum of medical devices (as illustrated in Figure 3) that have been conceived and rigorously assessed by involving endusers. The majority of the devices were seizure detection devices (44%) and healthcare / clinical information systems (40%) such as Software as Medical Device, web-based tools, electronic health records, and videoconferencing systems. Vagus Nerve Stimulator systems represented 9% of the studies found, followed by EEG (5%) and 1 study on an automated injection system (2%).

223

#### **3.2** Types of medical devices users involved in MDD and assessment.

A wide range of users were involved in the MDD process, including clinicians, PWE, carers, family members and persons with different disabilities and impairments (Figure 4). PWE were the users more frequently involved (40%, N = 3), followed by the PWE alongside CG (27%, N = 15) and HP (11%, N = 6). CG and HP alone were the users less frequently involved.

230

## **3.3 Extent of user involvement by stage of the medical device lifecycle**

The findings of the selected studies, especially the stages of the development of new medical devices, and methods used for capturing user perspectives by stages of the medical device lifecycle, are summarized in Figure 5 and Table S1. In 93% (N= 51) of the studies, users were involved in one stage of the medical device lifecycle especially in the deployment stage, and in the remaining studies users were involved in 2 (5%, N = 3) or 3 (2%, N = 1) stages of the lifecycle. Single-stage involvement was predominant in the deployment phase during which the product is already in the market, as reported in 45% (N = 25) of the studies, followed by concept stages in 25% (N = 14), when all uncertainties such as the clinical need definition, customer requirements and needs, finances, reimbursement strategy, team selection, or legal aspects must be considered. Two-stage combinations were between design and testing and trials in 5% (N = 3). Three-stage combinations for user involvement were between concept, design, and testing and trials stages in 2% (N = 1), which is shown in Figure 5.

All other studies are less comprehensive as their models only encompass one stage.

246

# 247 3.4 Methods used for capturing users' perspectives

Our review shows that several methods were designed to involve users, often requiring the 248 combination of both qualitative methods to evaluate parameters from a numerical point of 249 250 view and quantitative methods to indicate the user's choices, thoughts, and feelings. Involving users and capturing their perspectives in the medical device technology lifecycle 251 concerned mostly surveys in 49% (N=43), usability testing in 20% (N=18), interviews in 252 19% (N=17), and focus groups in 11% (N=10) of the studies (Figure 6). These methods are 253 mapped against the medical device lifecycle stages where they were used (Table 2). Some of 254 the studies used more than one method of inquiry. 255

Surveys and focus groups were used in all four medical device lifecycle stages where the users were involved. Typically, surveyed individuals were asked to respond to the questions in a yes/no manner, on a Likert-type scale (e.g., very often to not at all often), or with openended responses. The choice of responses was dictated by the investigator and the medical device (if one was used). The selection of the type of response desired was often made based on the difficulty of the question asked and the depth of knowledge and level of precision the investigator would like to have about a particular factor <sup>74</sup>.

Usability tests and interviews were most commonly used for involving users and capturing 263 their perspectives across three stages of the medical device lifecycle. During usability tests, 264 various data collection methods were used to collect both qualitative and quantitative data. 265 Results such as time to complete tasks, or errors made during tasks, were easy to understand 266 and compare. In its simplest form, a usability test just involved users performing a number of 267 typical tasks and then reporting their experiences of using the device, i.e., what, in their 268 opinion, worked well and what was problematic in the device placement <sup>43</sup>. When testing an 269 existing or prototype device to identify areas for improvement for example, qualitative data 270 was more useful <sup>47</sup>. In some of the reviewed studies, the developers observed users 271 performing scenario-based usability tests to identify shortcomings or areas for improvement 272 <sup>49</sup> and/or asked the user to report their experiences in follow-up interviews <sup>56</sup> or through user-273 274 centered methods such as empathy interviews, empathy mapping, and persona development as they complete the task <sup>64</sup>. Sometimes quantitative data were collected during usability 275 tests, such as the time taken to complete a task using the device or the number of errors made 276 whilst performing the task <sup>42</sup>. Interviews were mainly semi-structured and face-to-face. The 277 factors on which information was routinely collected in these studies include socio-278 demographic characteristics, lifestyle practices, medical history, and use of medical devices. 279

Finally, our systematic review revealed that almost half of the papers we retrieved incorporated 2 or more methods to evaluate user perspectives throughout the MDD process. For example, a scoping method such as exploratory interviews <sup>65</sup> or a focus group <sup>51</sup> were used to specify the needs and requirements of the users with an evaluative method such as a usability test <sup>65</sup> or survey <sup>51</sup> then used respectively at a later stage to determine whether these have been met.

# **4. DISCUSSION**

Successful medical device innovation requires research beyond technology-centred or technocentric design approaches to embrace user-centred methods 9. Employing formal methods to involve users in the MDD process should increase the probability that devices meet proper clinical goals, comply with technical standards, are cost-effective and meet ethical norms <sup>75</sup>.

292

# 293 **4.1 Types of devices**

In this review a substantial proportion of the devices pertained to seizure detection, and 294 healthcare and clinical information systems. This distribution aligns with previous studies <sup>77,</sup> 295  $^{78}$  that highlight the predominant focus on seizure forecasting and detection in epilepsy 296 research, underscoring the profound impact of seizures' unpredictability in this condition. 297 Notably, only 5 VNS and 3 EEG based systems were found in our literature search. 298 Moreover, among the 23 commercially available seizure detection devices and tools in the 299 US and Europe, reported by Shum, Friedman<sup>79</sup>, only Nightwatch, Epicare, Epilog, Sensor 300 301 Dots and GeneActiv were identified to have involved users in the MDD process predominantly in the deployment phase <sup>27, 37, 39, 50</sup>. This indicates a notable discrepancy in the 302 extent of user involvement in the development of commercially available devices for epilepsy 303 management. As highlighted by Hagedorn, Krishnamurty, Grosse<sup>80</sup>, the disclosure of user 304 involvement might be limited due to safety, privacy, and other ethical concerns that are 305 unique to medical environments and contexts. Nevertheless, these results highlight a potential 306 area for further research and improvement. 307

# 308 4.2 Types of users

The development of better products requires an in-depth understanding of all types of users, their activities, and their needs <sup>81</sup>. In epilepsy, prior research has demonstrated that

distinctions among users, including PWE, CG or HP can influence the delineation of user-311 specific requirements <sup>28</sup>. Consequently, similar factors were appropriately considered in this 312 study. Our review reveals that various types of medical devices are developed and assessed 313 by PWE, CG and HP. These different groups of healthcare technology users' characteristics, 314 skills and working environment may be different, which is worth considering when 315 developing health care technologies from the users' perspective. It must be mentioned, 316 317 however, that in assessing user needs, there is a substantial bias towards considering the needs of HP in contrast to PWE and CG. It is vital, therefore, that a range of users are 318 consulted to get as wide an array of input as possible <sup>82</sup>. Our review showed that PWE and 319 CG are the users more involved in the MDD process. These users are likely to be a non-320 medical, heterogeneous group, including family members. As a result, their background, age, 321 level of training, physical and mental fitness, and language knowledge vary considerably. 322 Furthermore, the context of use is hard to predict and likely to be less controlled, when 323 compared to a healthcare setting where standardised procedures and protocols are usually in 324 effect. Therefore, understanding their individual needs is imperative for a successful device 325 development process, and product quality and safety <sup>14, 16</sup>, which might be the reason why 326 these are more involved. 327

#### 328 **4.3 Methods of involvement**

In the process of designing and developing medical devices, biomedical innovators have at their disposal a range of formal methods to incorporate user requirements. Our review shows that four methods were used to involve users in the MDD process, despite several other available approaches could have been considered such as heuristic evaluation, journey mapping<sup>83</sup>, and cognitive walkthrough <sup>84</sup>. The majority of the studies used surveys, probably due to their effectiveness in gathering user feedback, namely through scalability, costeffectiveness, standardization of data, anonymity, and quick data collection <sup>85</sup>. With increasing attention being paid to patient-reported outcomes by funding agencies, measures of patient-centred factors, such as quality of life, depression, anxiety, cognitive, and functional status, are increasingly included in these surveys. Usability evaluation was the second most used method, reported in 20% of the reviewed studies, probably due to the current focus on improving usability and reducing human error within the medical device industry, and their need for regulatory agencies' certification <sup>86</sup>.

Depending on the purpose and context of the medical device, understanding user needs and 342 eliciting their perspectives for developing medical devices could entail a combination of 343 different methods <sup>14</sup>. Our systematic review revealed that nearly half of the papers we 344 retrieved incorporated two or more methods to evaluate user perspectives throughout the 345 MDD process. The identified use of multiple qualitative and quantitative methods in 346 combination with specific design methods is in line with the most recent literature which 347 highlights the importance of multi-method human-centred design approaches for the 348 development of health innovations comprising several design cycles<sup>87</sup>. 349

350

#### 351 **4.4 Stages of MDD**

352 Human-centred design should be central to all MDD to ensure that user needs are met. It is recommended that user-centred design should begin early, and continue throughout device 353 development <sup>88</sup>. Although we have found that users were involved in four out of the five 354 355 stages of the MDD process - concept, design, testing and trials, and deployment stages - none of the medical devices identified was assessed in all of these four stages. Moreover the 356 predominance of studies found in the deployment phase suggests that devices may lack 357 358 sufficient user input during their development, since the form and function has already been determined, and the ability to innovate based on user needs is limited due to a number of 359

fixed parameters <sup>3</sup>. Consequently, the medical devices found in this review may only partially
meet user requirements or fail to meet user requirements which could result in suboptimal
user experiences, higher modification costs, and missed opportunities for innovation.

363

#### 364 **4.5 Regulatory view**

Despite the fact that regulatory authorities such as Food and Drug Administration (FDA) and 365 European Medicines Agencies (EMA) and international standards organizations have 366 increasingly emphasized the importance of the employing formal methods for users' 367 involvement in the MDD as a critical factor in ensuring the effectiveness, safety, and 368 usability of medical devices <sup>89, 90</sup>, the involvement of users in the MDD process in epilepsy 369 remains marginal. Our systematic review revealed that users were only involved in the MDD 370 371 process of 13 commercially available medical devices for epilepsy management with most of the involvement being performed at the end of the MDD process in the deployment phase. 372 These results are in line with other therapeutic areas, as medical device manufacturers often 373 do not consider the benefit of employing formal human factors engineering methods within 374 the MDD process<sup>7</sup>. This gap suggests that the appropriate employment of formal methods by 375 manufacturers is unlikely to occur to significant levels without deliberate efforts to encourage 376 and support manufacturers in doing so. Alternatively, the implementation of such methods 377 could assume a mandatory character, being dictated to manufacturers by standards and 378 379 purchasing agencies.

# 380 5. LIMITATIONS

This systematic review adopted the MDD cycle comprising 5 phases accordingly with Shah, Robinson <sup>16</sup>. However, there is a lack of standardization of the MDD life cycle phases. WHO has yet to publish the medical device innovation part of the WHO medical device technical

series, where it is expected to contribute to the standardization of the stages of the MDD 384 process. Moreover, one limitation of this systematic review lies in the potential exclusion of 385 medical devices developed by HP, whose contributions, though integral to the development 386 phase, may not be explicitly reported in dedicated studies. Moreover, our review is contingent 387 on published studies, and thus, it might not capture unpublished research, proprietary 388 assessments by companies, or start-up initiatives aimed at gathering end-users' feedback. This 389 390 limitation highlights the potential underrepresentation of critical insights and developments in the field. The underreporting of user involvement in the MDD process, especially in epilepsy 391 392 management, results in a missed opportunity for the broader medical community. Theoretically, once IP rights are secured, companies could safely disclose their methods of 393 user involvement without jeopardizing their competitive position. However, the prevalent 394 medical device industry practice of non-disclosure prevents the sharing of potentially 395 beneficial experiences. Such transparency could foster an environment of collaborative 396 improvement, motivating others to adopt user-centric approaches in device development. The 397 lack of published information on user involvement methods in peer-reviewed journals hinders 398 the opportunity for cross-learning and iterative enhancements in medical device design. This 399 gap in knowledge dissemination ultimately impacts the quality and efficacy of devices 400 developed for epilepsy care, as well as other medical fields. Additionally, our review found 401 only 55 papers on user involvement or acceptability, likely because these metrics are often 402 403 embedded within the paper rather than highlighted in the abstract or title. This may have inadvertently excluded relevant studies, suggesting there could be more instances of user 404 involvement not captured in our review. 405

# 406 6. CLINICAL RELEVANCE OR FUTURE DIRECTIONS

This article provides a review and a conceptual understanding of the main user involvementresearch trends in MDD. The reviewed studies examined the medical-device usability

concept from three viewpoints: PWE, CGs and HPs. In this review, 55 scientific sources 409 related to user involvement in the medical device design and development in epilepsy were 410 analysed and systematized. The following were discussed: (i) PWE are the users more 411 involved in the MDD process; (ii) actual assessments may be applied differently for different 412 medical devices with a higher prevalence for surveys and usability testing; (iii) formal 413 methods for user involvement in the MDD process can be selected differently depending on 414 415 the type of product; (iv) users are involved in 4 stages of the MDD process; (v) although regulatory guidelines are published to address user involvement in MDD process, future 416 417 formal guidelines are needed to promote widespread of user involvement in MDD process in epilepsy. 418

419

420 Aut

## Author Contributions

J.F., R.P., C.C., J.C. and L.L. were responsible for conceptualisation, study design, and search strategy for this Review. J.F. and R.P. carried out the systematic review. C.C. adjudicated disagreements. J.F. carried out the statistical analyses. J.F. and R.R. drafted the manuscript. All authors critically revised the manuscript, approved its submitted version, and accept responsibility for its content. The article is the original work of the authors and has not been previously published, nor is it currently under consideration by any other journal.

427

428 Acknowledgments

This systematic review was funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them. The

433	work of J.C. is partially financed by National Funds through the Portuguese funding agency,			
434	FCT - Fundação para a Ciência e a Tecnologia, within project LA/P/0063/2020. DOI			
435	10.54499/LA/P/0063/2020   https://doi.org/10.54499/LA/P/0063/2020. C.C. is supported by a			
436	Scientific Employment Stimulus contract (2020.00067.CEECIND) from Fundação para a			
437	Ciência e a Tecnologia.			
438				
439	Disclosure of Conflicts of Interest			
440	The authors declare no competing interests.			
441				
442	Ethical Approval			
443	We confirm that we have read the Journal's position on issues involved in ethical			
444	publication and affirm that this report is consistent with those guidelines.			
444 445	publication and affirm that this report is consistent with those guidelines.			
	<ul><li>publication and affirm that this report is consistent with those guidelines.</li><li>7. REFERENCES</li></ul>			
445				
445 446	7. REFERENCES			
445 446 447	<ul> <li>7. REFERENCES</li> <li>1. Ong JS, Wong SN, Arulsamy A, Watterson JL, Shaikh MF. Medical Technology: A</li> </ul>			
445 446 447 448	<ul> <li>7. REFERENCES</li> <li>1. Ong JS, Wong SN, Arulsamy A, Watterson JL, Shaikh MF. Medical Technology: A Systematic Review on Medical Devices Utilized for Epilepsy Prediction and Management Curr</li> </ul>			
445 446 447 448 449	<ul> <li>7. REFERENCES</li> <li>1. Ong JS, Wong SN, Arulsamy A, Watterson JL, Shaikh MF. Medical Technology: A Systematic Review on Medical Devices Utilized for Epilepsy Prediction and Management Curr Neuropharmacol. 2022;20:950-964.</li> </ul>			
445 446 447 448 449 450	<ul> <li>7. REFERENCES</li> <li>1. Ong JS, Wong SN, Arulsamy A, Watterson JL, Shaikh MF. Medical Technology: A Systematic Review on Medical Devices Utilized for Epilepsy Prediction and Management Curr Neuropharmacol. 2022;20:950-964.</li> <li>2. Hubbard I, Beniczky S, Ryvlin P. The Challenging Path to Developing a Mobile Health</li> </ul>			
445 446 447 448 449 450 451	<ul> <li>7. REFERENCES</li> <li>1. Ong JS, Wong SN, Arulsamy A, Watterson JL, Shaikh MF. Medical Technology: A Systematic Review on Medical Devices Utilized for Epilepsy Prediction and Management Curr Neuropharmacol. 2022;20:950-964.</li> <li>2. Hubbard I, Beniczky S, Ryvlin P. The Challenging Path to Developing a Mobile Health Device for Epilepsy: The Current Landscape and Where We Go From Here Front Neurol.</li> </ul>			

455 for Design Innovation Management Conference 2019. United Kingdom: Academy for Design

456 Innovation Management; 2019. p. 1-19.

457 4. FDA. Applying Human Factors and Usability Engineering to Medical Devices. 2016.

458 5. Bruno E, Viana PF, Sperling MR, Richardson MP. Seizure detection at home: Do devices on
459 the market match the needs of people living with epilepsy and their caregivers? Epilepsia. 2020
460 Nov;61 Suppl 1:S11-S24.

461 6. Vaisson G, Provencher T, Dugas M, Trottier ME, Chipenda Dansokho S, Colquhoun H, et al.
462 User Involvement in the Design and Development of Patient Decision Aids and Other Personal Health
463 Tools: A Systematic Review Med Decis Making. 2021 Apr;41:261-274.

464 7. Money AG, Barnett J, Kuljis J, Craven MP, Martin JL, Young T. The role of the user within
465 the medical device design and development process: medical device manufacturers' perspectives
466 BMC Medical Informatics and Decision Making. 2011 2011/02/28;11:15.

Arthur G Money JB, Jasna Kuljis, Michael P Craven, Jennifer L Martin, Terry Young. The
role of the user within the medical device design and development process: medical device
manufacturers' perspectives BMC Medical Informatics and Decision Making. 2011;11:12.

470 9. Rodriguez NM, Burleson G, Linnes JC, Sienko KH. Thinking Beyond the Device: An
471 Overview of Human- and Equity-Centered Approaches for Health Technology Design Annu Rev
472 Biomed Eng. 2023 Jun 8;25:257-280.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ. 2021 Mar
29;372:n71.

476 11. WHO. Global Model Regulatory Framework for Medical Devices including in vitro477 diagnostic medical devices. 2017.

478 12. Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and
479 SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative
480 systematic reviews BMC Health Serv Res. 2014 Nov 21;14:579.

481 13. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative
482 research: a synthesis of recommendations Acad Med. 2014 Sep;89:1245-1251.

483 14. Shah SG, Robinson I, AlShawi S. Developing medical device technologies from users'
484 perspectives: a theoretical framework for involving users in the development process Int J Technol
485 Assess Health Care. 2009 Oct:25:514-521.

486 15. Maresova P, Klimova B, Honegr J, Kuca K, Ibrahim WNH, Selamat A. Medical Device
487 Development Process, and Associated Risks and Legislative Aspects-Systematic Review Front Public
488 Health. 2020;8:308.

489 16. Shah SG, Robinson I. User involvement in healthcare technology development and
490 assessment: structured literature review Int J Health Care Qual Assur Inc Leadersh Health Serv.
491 2006;19:500-515.

492 17. Hufford BJ, Glueckauf RL, Webb PM. Home-based, interactive videoconferencing for
493 adolescents with epilepsy and their families Rehabilitation Psychology. 1999;44:176-193.

494 18. Zamponi N, Rychlicki F, Corpaci L, Cesaroni E, Trignani R. Vagus nerve stimulation (VNS)
495 is effective in treating catastrophic 1 epilepsy in very young children Neurosurg Rev. 2008
496 Jul;31:291-297.

497 19. DiIorio C, Escoffery C, McCarty F, Yeager KA, Henry TR, Koganti A, et al. Evaluation of
498 WebEase: an epilepsy self-management Web site Health Educ Res. 2009 Apr;24:185-197.

20. Schulze-Bonhage A, Sales F, Wagner K, Teotonio R, Carius A, Schelle A, et al. Views of
patients with epilepsy on seizure prediction devices Epilepsy Behav. 2010 Aug;18:388-396.

501 21. Koo YS, Yang KS, Seok HY, Lee SK, Lee IK, Cho YW, et al. Characteristics of patients with
502 epilepsy who use a website providing healthcare information about epilepsy in South Korea Epilepsy
503 Behav. 2012 Oct;25:156-161.

Vonhofen G, Evangelista T, Lordeon P. Nursing benefits of using an automated injection
system for ictal brain single photon emission computed tomography J Neurosci Nurs. 2012
Apr;44:91-95; quiz 96-97.

507 23. Thygesen KS, Sabers A. Promising effect of vagal stimulation in Danish patients with
508 epilepsy Dan Med J. 2013 Mar;60:A4597.

509 24. Brunnhuber F, Amin D, Nguyen Y, Goyal S, Richardson MP. Development, evaluation and
510 implementation of video-EEG telemetry at home Seizure. 2014 May;23:338-343.

511 25. Askamp J, van Putten MJ. Mobile EEG in epilepsy Int J Psychophysiol. 2014 Jan;91:30-35.

512 26. Hoppe C, Feldmann M, Blachut B, Surges R, Elger CE, Helmstaedter C. Novel techniques for
513 automated seizure registration: Patients' wants and needs Epilepsy Behav. 2015 Nov;52:1-7.

514 27. van Andel J, Leijten F, van Delden H, van Thiel G. What makes a good home-based 515 nocturnal seizure detector? A value sensitive design PLoS One. 2015;10:e0121446. 516 28. Van de Vel A, Smets K, Wouters K, Ceulemans B. Automated non-EEG based seizure 517 detection: Do users have a say? Epilepsy Behav. 2016 Sep;62:121-128. 518 29. Newman C, Shankar R, Hanna J, McLean B, Osland A, Milligan C, et al. Developing an 519 Evidence-Based Epilepsy Risk Assessment eHealth Solution: From Concept to Market JMIR Res 520 Protoc. 2016 Jun 7;5:e82. 521 30. Patel AD, Moss R, Rust SW, Patterson J, Strouse R, Gedela S, et al. Patient-centered design 522 criteria for wearable seizure detection devices Epilepsy Behav. 2016 Nov;64:116-121. 523 31. Sauro KM, Holroyd-Leduc J, Wiebe S, Quan H, Cooke L, Cross JH, et al. Knowledge 524 translation of an online tool to determine candidacy for epilepsy surgery evaluation Neurol Clin Pract. 525 2016 Aug;6:304-314. 32. 526 Tovar Quiroga DF, Britton JW, Wirrell EC. Patient and caregiver view on seizure detection devices: A survey study Seizure. 2016 Oct;41:179-181. 527 528 33. Modi AC, Schmidt M, Smith AW, Turnier L, Glaser N, Wade SL. Development of a web-529 based executive functioning intervention for adolescents with epilepsy: The Epilepsy Journey Epilepsy Behav. 2017 Jul;72:114-121. 530 531 34. Ali R, Elsayed M, Kaur M, Air E, Mahmood N, Constantinou J, et al. Use of social media to assess the effectiveness of vagal nerve stimulation in Dravet syndrome: A caregiver's perspective J 532 Neurol Sci. 2017 Apr 15;375:146-149. 533 534 35. Halford JJ, Sperling MR, Nair DR, Dlugos DJ, Tatum WO, Harvey J, et al. Detection of 535 generalized tonic-clonic seizures using surface electromyographic monitoring Epilepsia. 2017 536 Nov;58:1861-1869. 537 36. Ozanne A, Johansson D, Hallgren Graneheim U, Malmgren K, Bergquist F, Alt Murphy M. 538 Wearables in epilepsy and Parkinson's disease-A focus group study Acta Neurol Scand. 2018 539 Feb;137:188-194. Arends J, Thijs RD, Gutter T, Ungureanu C, Cluitmans P, Van Dijk J, et al. Multimodal 540 37. 541 nocturnal seizure detection in a residential care setting: A long-term prospective trial Neurology. 2018 542 Nov 20;91:e2010-e2019.

38. Afra P, Bruggers CS, Sweney M, Fagatele L, Alavi F, Greenwald M, et al. Mobile Software
as a Medical Device (SaMD) for the Treatment of Epilepsy: Development of Digital Therapeutics
Comprising Behavioral and Music-Based Interventions for Neurological Disorders Front Hum
Neurosci. 2018;12:171.

Meritam P, Ryvlin P, Beniczky S. User-based evaluation of applicability and usability of a
wearable accelerometer device for detecting bilateral tonic-clonic seizures: A field study Epilepsia.
2018 Jun;59 Suppl 1:48-52.

Janse SA, Dumanis SB, Huwig T, Hyman S, Fureman BE, Bridges JFP. Patient and caregiver
preferences for the potential benefits and risks of a seizure forecasting device: A best-worst scaling
Epilepsy Behav. 2019 Jul;96:183-191.

41. Chiang S, Moss R, Patel AD, Rao VR. Seizure detection devices and health-related quality of
life: A patient- and caregiver-centered evaluation Epilepsy Behav. 2020 Apr;105:106963.

Bruno E, Biondi A, Thorpe S, Richardson MP, Consortium R-C. Patients self-mastery of
wearable devices for seizure detection: A direct user-experience Seizure. 2020 Oct;81:236-240.

Bruno E, Biondi A, Bottcher S, Lees S, Schulze-Bonhage A, Richardson MP, et al. Day and
night comfort and stability on the body of four wearable devices for seizure detection: A direct userexperience Epilepsy Behav. 2020 Nov;112:107478.

Khan A, Peechatka A, Dias NR, Lima V, Seddo M, Inja A, et al. Patient Perspective in the
Development of Electronic Patient-Reported Outcomes (ePROs) in Seizure Disorders: A PatientCentric Approach Patient Prefer Adherence. 2020;14:13-21.

563 45. Beck M, Simony C, Zibrandtsen I, Kjaer TW. Readiness among people with epilepsy to carry
564 body-worn monitor devices in everyday life: A qualitative study Epilepsy Behav. 2020
565 Nov;112:107390.

566 46. Thompson ME, Goodwin R, Ojeda A, Morris L, Fairman AD. User Preferences for the
567 Design of a Mobile Health System to Support Transition-Age Youth With Epilepsy J Pediatr Health
568 Care. 2020 May-Jun;34:e28-e36.

569 47. Simblett S, Matcham F, Curtis H, Greer B, Polhemus A, Novak J, et al. Patients'

570 Measurement Priorities for Remote Measurement Technologies to Aid Chronic Health Conditions:

571 Qualitative Analysis JMIR Mhealth Uhealth. 2020 Jun 10;8:e15086.

572 48. Simblett SK, Biondi A, Bruno E, Ballard D, Stoneman A, Lees S, et al. Patients' experience
573 of wearing multimodal sensor devices intended to detect epileptic seizures: A qualitative analysis
574 Epilepsy Behav. 2020 Jan;102:106717.

49. Yoo S, Lim K, Baek H, Jang SK, Hwang GY, Kim H, et al. Developing a mobile epilepsy
management application integrated with an electronic health record for effective seizure management
Int J Med Inform. 2020 Feb;134:104051.

578 50. Nasseri M, Nurse E, Glasstetter M, Bottcher S, Gregg NM, Laks Nandakumar A, et al. Signal
579 quality and patient experience with wearable devices for epilepsy management Epilepsia. 2020
580 Nov;61 Suppl 1:S25-S35.

51. Buchhalter JR, Scantlebury MH, D'Alfonso S, Pablo Appendino J, Bello Espinosa L, Brooks
BL, et al. Creation and implementation of an electronic health record note for quality improvement in
pediatric epilepsy: Practical considerations and lessons learned Epilepsia Open. 2021 Jun;6:345-358.

584 52. Grzeskowiak CL, Dumanis SB. Seizure Forecasting: Patient and Caregiver Perspectives Front
585 Neurol. 2021;12:717428.

586 53. Cote J, Beaudet L, Auger P, Rouleau G, Chicoine G, Leger V, et al. Evaluation of a webbased virtual nursing intervention to support self-management among adults with epilepsy: A mixedmethods study Epilepsy Behav. 2021 Jan;114:107581.

589 54. Bruno E, Biondi A, Richardson MP, Consortium O. Digital semiology and time-evolution
590 pattern of bio-signals in focal onset motor seizures Seizure. 2021 Apr;87:114-120.

55. Herrera-Fortin T, Bou Assi E, Gagnon MP, Nguyen DK. Seizure detection devices: A survey
of needs and preferences of patients and caregivers Epilepsy Behav. 2021 Jan;114:107607.

593 56. Olsen LS, Nielsen JM, Simony C, Kjaer TW, Beck M. Wearables in real life: A qualitative
594 study of experiences of people with epilepsy who use home seizure monitoring devices Epilepsy
595 Behav. 2021 Dec;125:108398.

596 57. Willems LM, Baier H, Bien CG, Bosebeck F, Dumpelmann M, Hamer HM, et al. Satisfaction
597 with and reliability of in-hospital video-EEG monitoring systems in epilepsy diagnosis - A German
598 multicenter experience Clin Neurophysiol. 2021 Sep;132:2317-2322.

599 58. Monfort E, Poulet C, Nahas C, Bakridan S, Clair L, Latour P. Clustering patients and
600 caregivers for technology design: A step prior to the design of an innovative technological device for
601 the detection of epileptic seizures Epilepsy Behav. 2021 Sep;122:108233.

602 59. Chiang S, Moss R, Black AP, Jackson M, Moss C, Bidwell J, et al. Evaluation and 603 recommendations for effective data visualization for seizure forecasting algorithms JAMIA Open. 604 2021 Jan;4:00ab009. 605 60. Sabers A, Aumuller-Wagner S, Christensen LR, Henning O, Kostov K, Lossius M, et al. 606 Feasibility of transcutaneous auricular vagus nerve stimulation in treatment of drug resistant epilepsy: 607 A multicenter prospective study Epilepsy Res. 2021 Nov;177:106776. 608 61. Siegel BI, Johnson M, Dawson TE, Kurzen E, Holt PJ, Wolf DS, et al. Reducing Prescribing

609 Errors in Hospitalized Children on the Ketogenic Diet Pediatr Neurol. 2021 Feb;115:42-47.

610 62. von Wrede R, Rings T, Schach S, Helmstaedter C, Lehnertz K. Transcutaneous auricular

611 vagus nerve stimulation induces stabilizing modifications in large-scale functional brain networks:

towards understanding the effects of taVNS in subjects with epilepsy Sci Rep. 2021 Apr 12;11:7906.

613 63. Hadady L, Klivenyi P, Fabo D, Beniczky S. Real-world user experience with seizure
614 detection wearable devices in the home environment Epilepsia. 2022 Feb 23.

615 64. Schmidt M, Glaser N, Riedy T, Rietta C, Huszti H, Wagner J, et al. Learning experience
616 design of an mHealth intervention for parents of children with epilepsy Int J Med Inform. 2022
617 Apr;160:104671.

618 65. Lazaro MJ, Alvaran A, Yun MH, Kim S. Mobile Health Application for Seizure
619 Management: A Human-Systems Integration Approach Hum Factors. 2022 Mar
620 25:187208221074427.

66. Macea J, Bhagubai M, Broux V, De Vos M, Van Paesschen W. In-hospital and home-based
long-term monitoring of focal epilepsy with a wearable electroencephalographic device: Diagnostic
yield and user experience Epilepsia. 2023 Apr;64:937-950.

624 67. van Leeuwen MMA, Droger MM, Thijs RD, Kuijper B. Nocturnal seizure detection: What
625 are the needs and expectations of adults with epilepsy receiving secondary care? Epilepsy Behav.
626 2023 Oct;147:109398.

627 68. Guerrero-Aranda A, Friman-Guillen H, González-Garrido AA. Acceptability by End-users of
628 a Standardized Structured Format for Reporting EEG Clinical EEG and neuroscience. 2023
629 Sep;54:483-488.

630 69. Lewis-Fung S, Tchao D, Gray HG, Nguyen E, Pardini S, Harris LR, et al. Designing virtual

reality exposure scenarios to treat anxiety in people with epilepsy: Phase 2 of the AnxEpiVR clinical
trial. 2023 2023-July-19;4. Original Research

70. Tchao D, Lewis-Fung S, Gray H, Pardini S, Harris LR, Appel L. Describing epilepsy-related
anxiety to inform the design of a virtual reality exposure therapy: Results from Phase 1 of the
AnxEpiVR clinical trial Epilepsy Behav Rep. 2023;21:100588.

636 71. Lennard S, Newman R, McLean B, Jory C, Cox D, Young C, et al. Improving nocturnal event
637 monitoring in people with intellectual disability in community using an artificial intelligence camera
638 Epilepsy Behav Rep. 2023;22:100603.

Hufford BJ, R.L. G, P.M. W. Home-based, interactive videoconferencing for adolescents with
epilepsy and their families Rehabilitation Psychology. 1999:176-193.

641 73. Bruno E, Biondi A, Böttcher S, Vértes G, Dobson R, Folarin A, et al. Remote Assessment of
642 Disease and Relapse in Epilepsy: Protocol for a Multicenter Prospective Cohort Study JMIR Res
643 Protoc. 2020 Dec 16;9:e21840.

544 74. Saczynski JS, McManus DD, Goldberg RJ. Commonly used data-collection approaches in
clinical research Am J Med. 2013 Nov;126:946-950.

646 75. Woudstra K, Tummers M, Rovers MM, Reuzel R. Innovators' views on involving users and
647 patients in surgical device development: a qualitative interview study. 2021;11:e050801.

648 76. Vibhute SM, Engelmann J, Verbic T, Maier ME, Logothetis NK, Angelovski G. Synthesis
649 and characterization of pH-sensitive, biotinylated MRI contrast agents and their conjugates with
650 avidin Organic & biomolecular chemistry. 2012 Dec 6.

77. Dumanis SB, French JA, Bernard C, Worrell GA, Fureman BE. Seizure Forecasting from
Idea to Reality. Outcomes of the My Seizure Gauge Epilepsy Innovation Institute Workshop eNeuro.
2017 Nov-Dec;4.

Kuhlmann L, Lehnertz K, Richardson MP, Schelter B, Zaveri HP. Seizure prediction - ready
for a new era Nat Rev Neurol. 2018 Oct;14:618-630.

656 79. Shum J, Friedman D. Commercially available seizure detection devices: A systematic review
657 J Neurol Sci. 2021 Sep 15;428:117611.

80. Hagedorn TJ, Krishnamurty S, Grosse IR. An information model to support user-centered
design of medical devices J Biomed Inform. 2016 Aug;62:181-194.

81. Staccini P, Joubert M, Quaranta JF, Fieschi D, Fieschi M. Modelling health care processes for
eliciting user requirements: a way to link a quality paradigm and clinical information system design
Int J Med Inform. 2001 Dec;64:129-142.

82. Smith V, Warty R, Nair A, Krishnan S, Sursas JA, da Silva Costa F, et al. Defining the
clinician's role in early health technology assessment during medical device innovation – a systematic
review BMC Health Services Research. 2019 2019/07/23;19:514.

666 83. Ly S, Runacres F, Poon P. Journey mapping as a novel approach to healthcare: a qualitative
667 mixed methods study in palliative care BMC Health Services Research. 2021 2021/09/04;21:915.

66884.Farzandipour M, Nabovati E, Sadeqi Jabali M. Comparison of usability evaluation methods

669 for a health information system: heuristic evaluation versus cognitive walkthrough method BMC

670 Medical Informatics and Decision Making. 2022 2022/06/18;22:157.

671 85. Dillman DA, Smyth JD, Christian LM. Internet, phone, mail, and mixed mode surveys: The
672 tailored design method, 4th ed. Hoboken, NJ, US: John Wiley & Sons Inc; 2014.

86. Bitkina OV, Kim HK, Park J. Usability and user experience of medical devices: An overview
of the current state, analysis methodologies, and future challenges International Journal of Industrial
Ergonomics. 2020 2020/03/01/;76:102932.

676 87. Gottgens I, Oertelt-Prigione S. The Application of Human-Centered Design Approaches in
677 Health Research and Innovation: A Narrative Review of Current Practices JMIR Mhealth Uhealth.
678 2021 Dec 6;9:e28102.

679 88. Martin JL, Clark DJ, Morgan SP, Crowe JA, Murphy E. A user-centred approach to
680 requirements elicitation in medical device development: a case study from an industry perspective
681 Appl Ergon. 2012 Jan;43:184-190.

89. U.S. Department of Health and Human Services FaDA, Center for Devices and Radiological
Health, Office of Device Evaluation. Applying human factors and usability engineering to medical
devices. Guidance for industry and Food and Drug Administration staff. FDA-2011-D-0469 2016.

685 90. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on
686 medical devices aDE, Regulation (EC) No 178/2002 and Regulation (EC) No1223/2009 and repealing
687 Council Directives 90/385/EEC and 93/42/EEC. 2017 O.J. (L 117) 1.

688

#### 690

# 691 Appendix 1 – Data Extraction Form

Author details	Study Design	Country of the study	Year of publication	Objectives	Stages/phases of the development of medical device	Medical Device

692

# 693 Figure legends

- 694 Figure 1 PRISMA Flowchart adopted for the present systematic review
- Figure 2 Number of publications per year (blue bars) and cumulative number (orange line)
- 696 of publications from 1999 to 2023, as of \*November 30, 2023. (N=55)
- 697 Figure 3 Types of medical devices developed and assessed by user involvement (N=55)
- 698 Figure 4 Included publications by types of users (N=55), CG caregivers; HP Health
- 699 Professionals; PWE Patients with Epilepsy.
- Figure 5 Included publications by products lifecycle stages (N=55)
- Figure 6 Methods used for capturing user perspectives (N=55).

- 703 Tables
- Table 1 Product Lifecycle Stages (Adapted from Shah, Robinson  $^{16}$ )

Medical Device Lifecycle Stage	Details	
Concept	Starts with idea generation and includes technical, financial, and commercial assessment	


Design	Involves product development process from (re)design to prototype development	
Testing and trials	Starts with prototype testing in-house and includes trials in the real field	
Production	Includes production on large scale supported by business and commercial rationale	
Deployment	Includes product marketing, launch, and use in the real field	


Table 2 – Methods used for capturing user perspectives by stages of the medical device 

707	lifecycl	e (N=55)	

Concept Stage	Design Stage	Test and trials stages	Deployment stage
Survey (11)	Focus Groups (4)	Usability Testing (6)	Interviews (10)
Focus Groups (2)	Interviews (3)	Survey (8)	Survey (16)
Interview (3)	Survey (4)	Focus Groups (3)	Usability Testing (6)
Usability Testing (1)	Usability Testing (4)		Focus Groups (3)

N-total publications included





Year

